Evaluation of the outcomes of newly diagnosed patients with high-risk myelodysplastic syndrome according to the initial therapeutical strategies chosen in usual clinical practice

References

• Grupo Español de Síndromes Mielodisplásicos (GESMD), Sociedad Española de Hematología y Hemoterapia (SEHH). Guías españolas de diagnóstico y tratamiento de los síndromes mielodisplásicos y la leucemia mielomonocítica crónica. Haematologica. 2012;97:5–46.
   PubMedGoogle Scholar
• Rahmé R, Adès L. An update on treatment of higher risk myelodysplastic syndromes. Expert Rev Hematol. 2019;12(1):61–70.
   PubMed Web of Science ®Google Scholar
• Rodríguez JH, Acosta I. Actualización en síndromes mielodisplásicos (SMD). Rev. Méd. Rosario. 2011;77:24–41.
   Google Scholar
• Komrokji RS, Bennett JM. Evolving classifications of the myelodysplastic syndromes. Curr Opin Hematol. 2007;14(2):98–105.
   PubMed Web of Science ®Google Scholar
• Grupo Español de Síndromes Mielodisplásicos (GESMD). Guías españolas para el diagnóstico y tratamiento de los SMD y la LMMC. 2020. http://www.gesmd.es/wp-content/uploads/2021/10/GuiaSMDLMMC2020.pdf
   Google Scholar
• Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079–2088.
   PubMed Web of Science ®Google Scholar
• Voso MT, Fenu S, Latagliata R, et al. Revised international prognostic scoring system (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO prognostic scoring system: validation by the gruppo romano mielodisplasie italian regional database. J Clin Oncol. 2013;31(21):2671–2677.
   PubMed Web of Science ®Google Scholar
• Valcárcel D, Sanz G, Ortega M, Grupo Español de Síndromes Mielodisplásicos (GESMD), et al. Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study. Lancet Haematol. 2015;2(6):e260-266–e266.
   Web of Science ®Google Scholar
• Comont T, Delavigne K, Cougoul P, et al. [Management of myelodysplastic syndromes in 2019: an update]. Rev Med Interne. 2019;40(9):581–589.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Haase D, Santini V, ESMO Guidelines Committee. Electronic address: [email protected], et al. Myelodysplastic syndromes: ESMO clinical practice guidelines for diagnosis, treatment and follow-up(†⋆). Ann Oncol. 2021;32(2):142–156.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7–17.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19(2):216–228.
   PubMed Web of Science ®Google Scholar
• Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6(10):1106–1117.
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Germing U, Götze KS, et al. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. Lancet Oncol. 2017;18(10):1338–1347.
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Kubasch AS, Homer-Bouthiette C, et al. Current challenges and unmet medical needs in myelodysplastic syndromes. Leukemia. 2021;35(8):2182–2198.
   PubMed Web of Science ®Google Scholar
• Bell JA, Galaznik A, Huelin R, et al. Systematic literature review of treatment options and clinical outcomes for patients with Higher-Risk myelodysplastic syndromes and chronic myelomonocytic leukemia. Clin Lymphoma Myeloma Leuk. 2018;18(4):e157–e166.
   PubMed Web of Science ®Google Scholar
• Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the world health organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–951.
   PubMed Web of Science ®Google Scholar
• Such E, Cervera J, Costa D, et al. Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica. 2011;96(3):375–383.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the international working group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419–425.
   PubMed Web of Science ®Google Scholar
• Kröger N, Sockel K, Wolschke C, et al. Comparison between 5-Azacytidine treatment and allogeneic Stem-Cell transplantation in elderly patients with advanced MDS according to donor availability (VidazaAllo study). J Clin Oncol. 2021;39(30):3318–3327.
   PubMed Web of Science ®Google Scholar
• Nakamura R, Saber W, Martens MJ, et al. Biologic assignment trial of Reduced-Intensity hematopoietic cell transplantation based on donor availability in patients 50-75 years of age with advanced myelodysplastic syndrome. J Clin Oncol. 2021;39(30):3328–3339.
   PubMed Web of Science ®Google Scholar
• Bernal T, Martínez-Camblor P, Sánchez-García J, Spanish Society of Hematology, et al. Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry. Leukemia. 2015;29(9):1875–1881.
   PubMed Web of Science ®Google Scholar
• Dinmohamed AG, van Norden Y, Visser O, et al. Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the dutch population-based PHAROS MDS registry. Leukemia. 2015;29(12):2449–2451.
   PubMed Web of Science ®Google Scholar
• Itzykson R, Thépot S, Quesnel B, Groupe Francophone des Myelodysplasies(GFM), et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood. 2011;117(2):403–411.
   PubMed Web of Science ®Google Scholar
• Mozessohn L, Cheung MC, Fallahpour S, et al. Azacitidine in the 'real-world’: an evaluation of 1101 higher-risk myelodysplastic syndrome/low blast count acute myeloid leukaemia patients in Ontario, Canada. Br J Haematol. 2018;181(6):803–815.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Stahl M, DeVeaux M, et al. Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates? Blood Cancer J. 2018;8(6):55.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, International Vidaza High-Risk MDS Survival Study Group, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223–232.
   PubMed Web of Science ®Google Scholar
• Garcia JS, Swords RT, Roboz GJ, et al. A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival. Leuk Res. 2021;104:106555.
   PubMed Web of Science ®Google Scholar
• Abel GA, Kim HT, Hantel A, et al. Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? Leukemia. 2021;35(4):1166–1175.
   PubMed Web of Science ®Google Scholar